Abstract
The NeoChord DS 1000 system offers a minimally invasive alternative for treating degenerative mitral regurgitation (MR), particularly in high-risk patients with previous aortic surgery. A 74-year-old male with a history of Bentall procedure presented with severe MR and dyspnea (NYHA III). Transapical mitral valve repair was performed using the NeoChord DS 1000 system. Three artificial chordae were implanted, significantly reducing MR. The patient had an uneventful recovery and was discharged in good condition after 8 days. This case demonstrates the NeoChord system's potential in high-risk patients where traditional MVR poses high risks. Transapical access avoids sternotomy and extracorporeal circulation, offering a safer alternative. The NeoChord DS 1000 system shows promise for high-risk patients and those with complex surgical histories, though further research is needed to confirm its long-term efficacy and durability.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
